anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Metabolic syndrome occurs in disease situations including cancer, cardiovascular disease, Parkinson's disease, sepsis and autoimmune disorders. Chronic inflammation of metabolic syndrome occurs because, during a first antigenic challenge, a second infection occurs. The body can deal with only one antigenic challenge at a time. The cytokine and endocrine response to the first challenge suppresses lymphocyte clone(s) selected by the second challenge so that only the innate immune system responds to the second challenge, and it is inadequate. A virulent secondary infection can result in death. A weak secondary challenge causes chronic infection. A vigorous secondary challenge while the response to the first is entering the adaptive immune phase can cause autoimmunity, insulin is a powerful stimulant to lymphocytes and awakens selected lymphocytes rendered inert by the cytokine/endocrine mix, which secrete cytokines to terminate the innate phase and restart the adaptive phase. Pathogens are destroyed, tumors eliminated and inflammations disappear.
PURPOSE:To provide the titled agent for external use, capable of increasing the concentration of activated vitamin D3 in the local tissue when administered to the local part of the human body, and expected to be effective as a remedy for arthrorheumatism, cancer, etc., by using an activated vitamin D3 as an active component. CONSTITUTION:An agent for external use, containing an activated vitamin D3 (e.g. 1alpha,25-dihydroxycholecalciferol, 1alpha-hydroxycholecalciferol, etc.) as an active component. The amount of the activated vitamin D3 is preferably 1ng-2 mg/g, especially 5ng-0.5mg/g. It can be used in the form of ointment, cream, solution, aerosol, etc. The concentration of the activated vitamin D3 can be increased remarkably at the administered part or its neighborhood when applied to the skin, mucous membrane, etc.
Stabilised seawater in the form of a viscous prod comprises Na alginate as gelling agent (pref. 40-80g/1) and benzalkonium chloride as germicide (0.5-1.5 cm3 of a 50% aq. soln. /1 seawater) and opt. also iodinated polyvinyl pyrrolidine. The compsn. is stable over long periods, is non-toxic germicidal, hypertonic and vasoconstrictive; useful in various dermatological applications, e.g. treatment of eczena superficial injuries, sunburn, acne etc. and as a vehicle or excipient for pharmaceutical, cosmetic and veterinary prods.
The taVNS treatment is performed at auricular cymba concha. The stimulation parameters are set as follows: train on-time of 2 seconds and off-time of a 3-second pulse width of 0.5 ms, pulse frequency of 25 Hz, and amplitude of 0-2 milliamp (at the maximum level tolerated by the subject).
PURPOSE: A method for displaying data for displaying quantitatively analysed medical information is provided to analyze a meaning of measurement data by supplying the medical information generated in a measurement system. CONSTITUTION: A communication unit(210) receives an identifier of a diagnosis target and a measurement data. A database(250) stores the measurement data matching with the identifier. A valid range setup unit(220) processes in order to setup effective value. A data converter(230) extracts the measurement data by using the identifier. The data converter converts the measurement value according to a display scale.
PURPOSE:The titled additive, consisting essentially of calcium alginate, and effective for treating and preventing hypertension. CONSTITUTION:A medical food additive, consisting essentially of calcium alginate, and effective for hypertension. The dosage form is powder, capsule, jelly, etc., and the dose thereof is preferably 50mg-2g/kg/day. The dose is mush higher than the usual intake range of aliginates used as food additive, e.g. the conventional thickener or stabilizer, etc. The above-mentioned calcium alginate is used for the purpose of producing the sodium excretion and hypotensive action to the last. Considerations may be given to suitable adjustment according to the amount of sodium in a diet taken at the same time. This has also the secondary effect on ranking the food as a calcium-enriched food or dietary food.
FIELD: medicine. ^ SUBSTANCE: invention relates to medicine, namely to ophthalmology, ophthalmic surgery, physiotherapy. In case of localization of inflammatory focus in orbit without involvement into the process of paraorbital areas hospitalisation of patient into ophthalmology department of hospital is carried out. Orbitotomy in one or more quadrants is performed. Traditional intensive therapy is carried out. In case of intraorbital complications second stage of treatment is carried out. 1% solution of nicotinic acid is introduced intravenously in dose 2 ml on the first day, with daily 0.5-1.0 ml increase on the following days until maximal therapeutic efficiency is achieved, after that, successively dose is daily reduced by 0.5-1.0 ml to initial dose. Additionally after each injection of nicotinic acid, intravenous drip infusion of 2% pentoxifylline 5 ml on physiological solution in dose 100-200 ml is carried out during 7-15 days. Parabulbarly dexason 0.4% in dose 0.5 ml is introduced. Intramuscularly introduced are lidase in dose 64 U, actovegin in dose 2 ml and proserin 0.05% in dose 1 ml daily during 10 days. Electrophoresis with 0.05% proserin is carried out alternately with 0.5% hydrocortosone emulsion endonasally in case of optic nerve neuritis and bath method - in case of affection of eye-moving muscles with course of 10-15 procedures. If inflammatory process spreads into orbit from anatomically adjacent regions hospitalisation into otolaryngology department or into department of maxillofacial surgery, or neurosurgery or septic department of hospital is carried out. Sanitation of primary focuses of purulent infection is carried out. Traditional intensive therapy, which includes antibacterial, detoxication, desensibilising, immunologic and vitamin therapy, is performed. In case of intraorbital complications second stage of treatment is carried out in ophthalmology department of hospital. ^ EFFECT: method ensures obtaining early functional and cosmetic effect, prevents spread of inflammatory process into skull cavity. ^ 5 ex, 2 dwg
Patients receive docetaxel as in arm I and bortezomib IV over 3-5 seconds on days 1, 8, and 15. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with responding or stable disease after 4 courses receive bortezomib alone as above in the absence of disease progression or unacceptable toxicity.
Swallowing is coordinated by hyoid muscle group, pharyngeal muscle and upper esophageal muscle, as well as the regulation of swallowing related functional brain area. Dysphagia refers to the inability to safely and effectively transport food from the mouth to the stomach to obtain adequate nutrition and water, resulting in eating difficulties. Studies have shown that swallowing disorders are mainly caused by stroke, brain trauma, neurodegenerative diseases (Alzheimer's disease, Parkinson's disease, multiple sclerosis and amyotrophic lateral sclerosis) and head and neck cancers (oral tumors, nasopharyngeal and laryngeal cancers). Moreover, the prevalence of dysphagia increases with age. Patients with dysphagia often have many complications, which may lead to dehydration, malnutrition, aspiration, pneumonia, etc., which greatly delays the recovery process of patients and reduces the quality of life of patients. Studies have shown that the swallowing network includes multiple brain regions, including the primary somatosensory cortex, primary motor cortex, bilateral premotor and auxiliary motor cortex, cingulate cortex, prefrontal, temporal, precuneus, subparietal lobule, cerebellum and cerebellum.

At present, there are some functional near-infrared spectroscopy studies on the swallowing function of healthy people, which mainly focus on healthy young subjects, and studies show that the incidence of swallowing disorders increases with age, the incidence of swallowing disorders in people over 50 years old is 5.5% \~ 8%, and swallowing disorders are mainly concentrated in middle-aged and elderly people. At present, there are no studies on swallowing function in middle-aged and elderly healthy subjects with functional near-infrared spectroscopy. The purpose of this study is to explore and compare the cortical activation patterns and lateralization in the swallowing task of healthy middle-aged and elderly people and young people by using functional near-infrared spectroscopy, providing a theoretical basis for the exploration of swallowing function and further providing new ideas for the treatment of patients with swallowing disorders.
Consecutive patients with available CZT-SPECT within 3 months of measuring FFR in the left anterior descending coronary artery. In these patients, correlation between angiography-derived IMR and hyperemic microvascular resistance will be assessed.
This study aimed to investigate the correlation between ossific nucleus volume and avascular necrosis (AVN) in pediatric patients diagnosed with developmental dysplasia of the hip (DDH). Analyzing 211 cases, including 119 open reduction (OR) and 92 closed reduction (CR) procedures, we quantified ossific nucleus volume using magnetic resonance imaging (MRI). Categorizing the OR group based on ossific nucleus volume revealed no statistically significant difference in AVN incidence. Similarly, in the CR cohort, there was no significant discrepancy in AVN occurrence between subgroups with or without the ossific nucleus. Logistic regression in CR identified the international hip dysplasia institute (IHDI) grade as a significant AVN risk factor (p = 0.007). IHDI grades 3 and 4 exhibited a 6.94 times higher likelihood of AVN compared to grades 1 and 2. Across CR and OR, neither initial age nor ossific nucleus volume emerged as AVN risk factors. In conclusion, ossific nucleus volume does not pose a risk for AVN in DDH children undergoing CR or OR, emphasizing the clinical significance of IHDI grading in predicting AVN risk during CR and the importance of early intervention to prevent treatment delays.
Melioidosis is caused by Burkholderia pseudomallei, a Gram-negative saprophytic environmental bacterium that is an important emerging tropical infection. There are an estimated 165,000 cases and 89,000 deaths world-wide each year. Eighty-four percent of cases are in SE Asia where mortality is 40%; far exceeding most recognised neglected tropical diseases. Pneumonia, secondary to either inhalation of B.pseudomallei or to bacteraemic spread to the lung is the commonest presentation (51%). Annually the highest burden (75%) of infection occurs in the rainy season in (75% in Thailand). Up to 80% patients have at least one recognised risk factor for melioidosis including; diabetes, alcohol-dependence, glucocorticoid therapy, chronic obstructive pulmonary disease (COPD), chronic renal disease and cancer. COPD and diabetes mellitus are amongst the top ten causes of death in Myanmar (2018). Patients with HIV have not been shown to have greater risk of B. pseudomallei than immunocompetent patients.

Melioidosis was discovered in Myanmar in 1911 by British pathologist Alfred Whitmore and his assistant CS Krishnaswami. Yet since 1949 there have been few published cases. Under-reporting is partly due to difficulty in diagnosing melioidosis. Clinical and radiological findings are indistinguishable from tuberculosis. Laboratory diagnosis is challenging, lack of facilities, expertise and awareness of B.pseudomallei results in missed diagnostic opportunities.

Culture is the gold-standard diagnostic method but requires appropriate facilities and expertise which are not readily available in many developing countries like Myanmar. A rapid diagnostic (RDT) test has been developed for low resource settings that has been evaluated in Laos and India. The InBios® Active Melioidosis DetectTM-Lateral Flow Assay (AMD-LFA) detects B.pseudomallei 6-deoxyheptan capsular polysaccharide antigen. Shaw et al demonstrated sensitivity 85.71% (CI:74.61% to 93.25%) and specificity 93.62% (CI:88.23% to 97.04%), with positive predictive value of 85.71% (CI: 75.98% to 91.92%) compared to culture. We propose to evaluate this test for the diagnosis of melioidosis pneumonia in Myanmar.
BACKGROUND: Even terminal cancer patients desire to walk to the toilet by themselves until the very last day. This study aimed to describe the walking ability of patients with spinal metastases at the end-of-life stage and identify the factors affecting this ability.
METHODS: Among 527 patients who first visited our multidisciplinary team for bone metastasis between 2013 and 2016, 56 patients who had spinal metastases with a Spinal Instability Neoplastic Score ≥7 and died during follow-up were included. We collected general clinical data, performance status, Frankel classification, epidural spinal cord compression scale and Spinal Instability Neoplastic Score at the first consultation. Patients' last day of walking and date of death were also examined. Univariate analyses (chi-squared tests) were performed to identify the factors that impacted walking ability 30 and 14 days before patients' death.
RESULTS: A total of 56 patients were extracted, and 57.1% (32/56) and 32.7% (16/49) of patients were ambulatory 30 and 14 days before death, respectively. Their performance status (P = 0.0007), Frankel grade (P = 0.012) and epidural spinal cord compression grade (P = 0.006) at the first examination, and administration of bone modifying agents during follow-up period (P = 0.029) were significantly related to walking ability 30 days before death. Among ambulatory patients 30 days before death, those with Spinal Instability Neoplastic Score ≥10 (P = 0.005), especially with high scores of collapse (P = 0.002) and alignment (P = 0.002), were less likely to walk 14 days before death. The walking period in the last month of their life was significantly longer in patients with total Spinal Instability Neoplastic Score 7-9 (P = 0.009) and in patients without collapse (P = 0.040) by the Wilcoxon test.
CONCLUSION: The progression of spinal metastasis, especially neurological deficit, at the initial consultation were associated with walking ability 30 days before death, and spinal stability might be crucial for preserving walking ability during the last month. Early diagnosis and implementation of appropriate bone management might be important for the end-of-life walking ability.
Investigators will use the ADAPT-ITT framework to adapt a life skills intervention to increase the desire to live and reduce suicide ideation among at-risk emerging adult sexual minorities. STARS will embed components of the Safety Plan Intervention as well as modules focused on promoting coping with discrimination, social support, and positive affect. Investigators will pilot test STARS using a Type 1 Effectiveness-Implementation Hybrid Design in a racially/ethnically diverse sample of 60 EASM who report past-month suicidal ideation. Investigators will recruit EASM through social media advertising and invite them to an in-person screening. Eligible participants will provide informed consent and complete a Safety Planning Intervention with a licensed clinician, given the high-risk nature of the sample. They then will be randomized to the control condition ("CC", n = 30) or STARS (n = 30). Participants will be assessed at 2, 4, and 6 months. Primary outcomes will be preliminary efficacy outcomes of suicidal ideation and behavior and hypothesized mechanisms of change (improved coping with discrimination, social support, positive affect) to estimate critical parameters for a future trial. Secondary outcomes will be RE-AIM framework indicators (reach, adoption, implementation, maintenance). Our aims are: Aim 1: To conduct a systematic suicide prevention adaptation of a life skills intervention (STARS) that incorporates safety planning content and targets coping, social support, and positive affect using the ADAPT-ITT framework. Aim 2: To examine preliminary efficacy (suicidal ideation and behaviors) and mechanisms of action of STARS, relative to our control condition (safety planning protocol alone), using a prospective RCT design. Aim 3: Using RE-AIM metrics, to examine whether STARS has preliminary evidence for impacting intervention implementation outcomes among EASM compared to the control arm.
Water for preparing dialysis solution. The water has a hydrogen concentration of 50-600 ppb and pH value of 7-10, meeting ISO13959. Additionally, the water is used to dilute dialysis agent containing glucose metabolized product of 50 ng/ml. The invention further comprises a dialysis solution formed by the water, a manufacture method of dialysis solution and a dialysis apparatus. The dialysis apparatus provides a water having hydrogen of 50-600 ppb and pH of 7-10 meeting ISO13959, accepts a dialysis agent containing glucose metabolized product of 50 ng/ml, and dilutes the dialysis agent with the water to form a dialysis solution. The dialysis solution of the invention can avoid adverse effects resulted from glucose metabolized product.
The study will be conducted with 70 infertile women. The intervention group (n = 35) will consist of infertile women who receive a psychosexual caring program, and the control group will consist of infertile women who receive standard care. Standard care includes the information given by the nurse about the treatment methods to be applied once. A total of 4 interviews will be held in the intervention group. In the first interviews, pre-test data will be taken. The psychosexual caring program will be conducted online as a group intervention. The psychosexual caring program includes interventions to promote body awareness, the meaning of sexuality, and marital relationships by gaining communication skills, sexual communication, body knowledge, information about sexual health, and its dimensions. After online interviews with groups, data will be collected for primary and secondary outcomes.
PURPOSE:To obtain a porous low-releasing medicinal preparation having high watercontent and high strength, by freezing an aqueous solution of a polyvinyl alcohol containing a pharmacologically active substance below the freezing point, separating into the ice phase and the polymer phase, and leaving the polymer phase at a low temperature above the freezing point to effect the crystallization of the polymer. CONSTITUTION:A concentrated aqueous solution of PVA containing a pharmacologically active substance and having a concentration of 10-30wt% is prepared, cooled to room temperature, and immediately frozen at -20 deg.C for 10-24hr to obtain a phase-separated structure having separated ice phase and polymer phase. The objective slow-releasing preparation containing the pharmacologically active substance in the porous hydrogel of PVA is produced by leaving the polymer phase at 0-10 deg.C for >=10hr, thereby proceeding the further crystallization of PVA. The PVA is preferably the one having a saponification degree of >=99mol% and a viscosity-average polymerization degree of >=1,700. The above slow-releasing preparation can be used in various forms to which slow-releasing property is required, e.g. suppository, transcutaneous agent, sublingual tablet, oral administration agent, etc.
Techniques are provided for controlling delivery of a therapeutic coating to a medical implant device. An identifier of the medical implant device may be received. It may be determined, based at least in part on the first identifier, that the first medical implant device is approved to receive the therapeutic coating. A coating applicator system may be switched from a locked state in which it is prohibited from applying the therapeutic coating to an unlocked state in which it is permitted to apply the therapeutic coating. The coating applicator system may, while in the unlocked state, apply the therapeutic coating to the first medical implant device. After the applying of the therapeutic coating, the coating applicator system may be switched from the unlocked state back to the locked state.
Rashes are dense and large in area, often treated with antibiotics, antihistamines, calcium supplements, and glucocorticoids (2 mg/kg/d) for 5 days. The rash does not subside or new rash still appears, and it frequently repeats more than 3 times during hospitalization.
Carcinogenesis and Mutagenesis

Palpable masses occurred in rats with high frequency after as few as 26 oral doses of brincidofovir at systemic exposures less than the expected human exposure based on the recommended dose of TEMBEXA. The masses diagnosed as mammary adenocarcinomas, carcinoma in squamous cell, Zymbal’s gland, uterus and small intestine and hemangiosarcomas in mesenteric and mediastinal lymph node, liver and abdominal cavity were observed in rats following long term (13-weeks and 26-weeks) dosing studies. No tumors occurred in rats after 9 twice-weekly intravenous doses, although rats were only followed for 14 days after the last administration. Based on these data and the unknown translation of nonclinical findings to clinical risk, TEMBEXA is considered a potential human carcinogen.

Brincidofovir was negative in a bacterial mutagenicity (Ames) assay and an in vivo micronucleus assay in mice. Brincidofovir was positive for increased structural chromosomal aberrations in the absence of metabolic activation in an in vitro assay.

Impairment of Fertility

In chronic dosing studies with orally administered brincidofovir, testicular effects were seen in both rats and monkeys. Monkeys administered twice weekly doses of brincidofovir via oral gavage for 9 months exhibited atrophy of the seminiferous tubules and hypospermia in the epididymides. Based on sperm analysis and histopathology, these findings demonstrated a trend towards recovery after a 6 month, post-dosing period. Rats administered brincidofovir via oral gavage twice weekly for 13 weeks exhibited decreased testes weights, depletion of spermatogenesis and hypospermia. Unlike in the monkey, recovery was not demonstrated in the rats following a 12-week post-dosing period.

In a rat fertility and early embryonic development study, administration of brincidofovir once daily beginning 15 days before cohabitation, during cohabitation and continuing through gestation day 7 resulted in decreased embryonal viability at 0.25 mg/kg/day, a dose that did not cause maternal toxicity. Male rats dosed twice weekly by oral gavage for 10 to 19 weeks had reduced sperm motility and a decrease in total sperm count. These effects resulted in reduced fertility during the first cohabitation period, and infertility during the second cohabitation period.

Brincidofovir exposures in both monkeys and rats were less than exposures seen in humans administered 200 mg brincidofovir. Studies conducted using intravenous brincidofovir to achieve clinically relevant exposures demonstrated diminished but ongoing spermatogenesis in the tubules of rats 15 weeks after administration of 3 doses of brincidofovir administered once weekly. The testicular pathology appears to be an effect on the mitotic spermatogonia.